While immunotherapy targeting the PD-1/PD-L1 axis shows promising outcomes in the treatment of different types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma, its effectiveness in patients with other solid tumors is limited [40]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.